Form 8-K - Current report:
SEC Accession No. 0000950170-23-007360
Filing Date
2023-03-10
Accepted
2023-03-10 17:19:19
Documents
12
Period of Report
2023-03-10
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K itos-20230310.htm   iXBRL 8-K 51323
  Complete submission text file 0000950170-23-007360.txt   168064

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT itos-20230310.xsd EX-101.SCH 2496
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT itos-20230310_pre.xml EX-101.PRE 9858
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT itos-20230310_lab.xml EX-101.LAB 13350
6 EXTRACTED XBRL INSTANCE DOCUMENT itos-20230310_htm.xml XML 4704
Mailing Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472
Business Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472 857-204-4583
iTeos Therapeutics, Inc. (Filer) CIK: 0001808865 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39401 | Film No.: 23724774
SIC: 2836 Biological Products, (No Diagnostic Substances)